Literature DB >> 19951572

Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats.

Hong Zhou1, Hao-ming Tian, Yang Long, Xiang-xun Zhang, Li Zhong, Li Deng, Xiao-he Chen, Xiu-qun Li.   

Abstract

BACKGROUND: Diabetic nephropathy is a common complication of diabetes mellitus. This study aimed to explore whether mesenchymal stem cells (MSCs) transplantation could attenuate diabetic nephropathy in experimental diabetic rats.
METHODS: Sprague-Dawley rats received a single intraperitoneal injection of streptozotocin (STZ) (60 mg/kg). Diabetic rats were randomized to four groups: diabetes control group (DC), ciclosporin A group (CsA), MSC group, and MSC + CsA group (MSCA). Bone marrow mesenchymal stem cells were cultured, identified and labeled by 5-bromo-2'-deoxyuridine (BrdU) in vitro. Then they were transplanted to diabetic rats via introcardiac infusion. Ciclosporin A was administered daily at 5 mg/kg. At 1, 2, 4, 8 weeks after transplantation, random blood glucose, urine albumin/creatinine ratio (Alb/Cr), endogenous creatinine clearance rate and renal mass index were tested. Renal morphology and labeled cells were examined.
RESULTS: Cultured MSCs expressed mesenchymal cell phenotype, and could be multidifferentiated to osteogenic and adipogenic cells. Labeled MSCs could be detected in the kidney of nephropathic rats, mainly in renal interstitium, but they did not propagate after engrafting in kidney. Over the course of the experiment, MSCA group showed a significant decrease in blood glucose compared with MSC group, CsA group and DC group (P < 0.05, respectively). The Alb/Cr in MSCA group and MSC group were significantly lower than CsA group and DC group (P < 0.05). And the Alb/Cr in MSCA group showed a significant decrease compared with MSC group (0.74 vs 0.84, P < 0.05). There was a significant difference in renal mass index between the MSCA group and DC group (5.66 vs 6.37, P < 0.05). No significant difference was found in creatinine clearance rate among 4 groups (P > 0.05). Treatment with MSC + CsA significantly ameliorated the morphology of diabetic kidney.
CONCLUSION: MSC could mildly ameliorate diabetic nephropathy by decreasing blood glucose, Alb/Cr ratio and renal mass index.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19951572

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  20 in total

Review 1.  Virus integration and genome influence in approaches to stem cell based therapy for andro-urology.

Authors:  Longkun Li; Deying Zhang; Peng Li; Margot Damaser; Yuanyuan Zhang
Journal:  Adv Drug Deliv Rev       Date:  2014-10-18       Impact factor: 15.470

Review 2.  Recent Progress in Stem Cell Therapy for Diabetic Nephropathy.

Authors:  Yang Liu; Sydney C W Tang
Journal:  Kidney Dis (Basel)       Date:  2015-12-05

Review 3.  Stem cell technology for the treatment of acute and chronic renal failure.

Authors:  Christopher J Pino; H David Humes
Journal:  Transl Res       Date:  2010-07-30       Impact factor: 7.012

Review 4.  The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease.

Authors:  Tomás P Griffin; William Patrick Martin; Nahidul Islam; Timothy O'Brien; Matthew D Griffin
Journal:  Curr Diab Rep       Date:  2016-05       Impact factor: 4.810

5.  Repeated systemic administration of human adipose-derived stem cells attenuates overt diabetic nephropathy in rats.

Authors:  Li Zhang; Kanghua Li; Xiangfei Liu; Diangeng Li; Congjuan Luo; Bo Fu; Shaoyuan Cui; Fei Zhu; Robert Chunhua Zhao; Xiangmei Chen
Journal:  Stem Cells Dev       Date:  2013-08-21       Impact factor: 3.272

6.  Metabolic and pancreatic effects of bone marrow mesenchymal stem cells transplantation in mice fed high-fat diet.

Authors:  Patricia de Godoy Bueno; Juliana Navarro Ueda Yochite; Graziela Fernanda Derigge-Pisani; Kelen Cristina Ribeiro Malmegrim de Farias; Lucimar Retto da Silva de Avó; Júlio César Voltarelli; Ângela Merice de Oliveira Leal
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

7.  Proregenerative Microenvironment Triggered by Donor Mesenchymal Stem Cells Preserves Renal Function and Structure in Mice with Severe Diabetes Mellitus.

Authors:  Fernando Ezquer; Maximiliano Giraud-Billoud; Daniel Carpio; Fabián Cabezas; Paulette Conget; Marcelo Ezquer
Journal:  Biomed Res Int       Date:  2015-06-08       Impact factor: 3.411

Review 8.  Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis.

Authors:  Diana A Papazova; Nynke R Oosterhuis; Hendrik Gremmels; Arianne van Koppen; Jaap A Joles; Marianne C Verhaar
Journal:  Dis Model Mech       Date:  2015-01-29       Impact factor: 5.758

9.  Icariside II ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats.

Authors:  Wenjie Tian; Hongen Lei; Ruili Guan; Yongde Xu; Huixi Li; Lin Wang; Bicheng Yang; Zhezhu Gao; Zhongcheng Xin
Journal:  Drug Des Devel Ther       Date:  2015-09-07       Impact factor: 4.162

Review 10.  Mesenchymal stem cell-based treatment for microvascular and secondary complications of diabetes mellitus.

Authors:  Grace C Davey; Swapnil B Patil; Aonghus O'Loughlin; Timothy O'Brien
Journal:  Front Endocrinol (Lausanne)       Date:  2014-06-06       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.